BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

USA
EnglishUK
EnglishIndia
EnglishAustralia
EnglishCanada
EnglishFrance
FrançaisSuisse
FrançaisEspaña
EspañolDeutschland
DeutschÖsterreich
DeutschSchweiz
DeutschBelgië
NederlandsNederland
NederlandsItalia
ItalianoSverige
Svenska
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.050 USD | +2.61% |
|
+3.78% | +20.35% |
02-12 | BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal | MT |
02-12 | BioCryst Pharmaceuticals, Inc. Launches ORLADEYO (berotralstat) in Portugal | CI |